Condition: Prostate Cancer · Sponsor: NYU Langone Health
Phase I/Ib, single arm trial of Two-Fraction Stereotactic Body Radiation Therapy (SBRT) with an MRI directed, dominant intraprostatic lesion (DIL), simultaneous integrated boost (SIB) based on genomic classification in the treatment of localized prostate cancer. The primary purpose of this study is to determine the feasibility and safety of two fraction SBRT in patients with localized prostate cancer.
This description comes directly from the study's public registry record.
Vianca Santos, MPH · 212-496-5845 · Vianca.santos@nyulangone.org
Always discuss trial participation with your own doctor first.
| NYU Langone Hospital - Long Island | Mineola, New York, United States | Recruiting |
| NYCyberKnife at Perlmutter Cancer Center | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05864196